Month: July 2018

TRICAPITAL welcomes Ryboquin acquisition of Nanogenics


TRICAPITAL has welcomed investee Ryobquin’s acquisition of gene therapy pioneers Nanogenics Limited. Ryboquin raised £4.45 million in its third funding round from new and existing share-holders to acquire Nanogenic Solutions. TRICAPITAL chairman Jamie Andrew said: “I’m delighted that TRICAPITAL has been able to support the acquisition of Nanogenics by Ryboquin. As Borders business angels, we’re […]